Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up – Still a Buy?

Genmab A/S (OTCMKTS:GNMSF) shares gapped up prior to trading on Tuesday . The stock had previously closed at $274.50, but opened at $289.16. Genmab A/S shares last traded at $289.16, with a volume of 66 shares traded.

Genmab A/S Stock Up 1.1%

The company has a market capitalization of $17.80 billion, a P/E ratio of 21.81 and a beta of 0.78. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. The company has a 50 day simple moving average of $263.80 and a two-hundred day simple moving average of $282.02.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.